Author:
Sandercock J,Parmar M K B,Torri V,Qian W
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Adams M, A'Hern RP, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD, Harper PG, Jayson GC, Kaye SB, Ledermann JA, Osborne RJ, Perren TJ, Poole CJ, Radford JA, Rustin GJ, Slevin ML, Smyth JF, Thomas H, Wilkinson PM (1998) Chemotherapy for ovarian cancer – a consensus statement on standard practice. Br J Cancer 78: 1404–1406
2. Adams M, Kerby IJ, Rocker I, Evans A, Johansen K, Franks CR (1989) A comparison of toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 28: 57–60
3. Advanced Ovarian Cancer Trialists Group (1998) Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomised trials. Br J Cancer 78: 1479–1487
4. Athanassiou A, Varthalitis J, Tsavaris N, Dimitriadis M, Moutzouridis G (1997) Superiority of carboplatin monochemotherapy over carboplatin-based polychemotherapy in ovarian cancer. Eur J Gynaecol Oncol 18: 420–425
5. Bolis G, Favalli G, Danese S, Zanaboni F, Mangili G, Scarabelli C, Tateo S, Valsecchi MG, Scarfone G, Richiardi G, Frigerio L, Melpignano M, Villa A, Parazzini F (1997) Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. J Clin Oncol 15: 1938–1944
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献